TD Cowen lowered the firm’s price target on Sage Therapeutics to $28 from $105 and keeps an Outperform rating on the shares. The firm said the company announced it received a CRL for their NDA of zuranolone for MDD but received approval for PPD as Zurzuvae with an expected 4Q launch after DEA scheduling.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SAGE:
- Sage Therapeutics downgraded to Hold at Canaccord after Zurzuvae CRL
- Sage Therapeutics downgraded to Neutral from Buy at Goldman Sachs
- Sage Therapeutics price target lowered to $19 from $45 at Mizuho
- Sage Therapeutics price target lowered to $27 from $50 at H.C. Wainwright
- Sage Therapeutics downgraded to Hold from Buy at Canaccord